-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Ocular Therapeutix, Raises Price Target to $30

Benzinga·06/18/2026 13:09:16
Listen to the news
Baird analyst Colleen Kusy maintains Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and raises the price target from $24 to $30.